Who is sponsoring NCT04470427?

NCT04470427 is sponsored by ModernaTX, Inc..

What condition does NCT04470427 study?

NCT04470427 studies SARS-CoV-2.

What drugs are being tested in NCT04470427?

Interventions: mRNA-1273, Placebo.

What is the status of NCT04470427?

NCT04470427 is currently COMPLETED.

Last reviewed 2024-03-21 · How we verify

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

NCT04470427 PHASE3 COMPLETED Results posted

The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to prevent COVID-19 for up to 2 years after the second dose of mRNA-1273.

Details

Lead sponsor	ModernaTX, Inc.
Phase	PHASE3
Status	COMPLETED
Enrolment	30415
Start date	Mon Jul 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Dec 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

SARS-CoV-2

Interventions

mRNA-1273
Placebo

Countries

United States